固生堂(02273.HK)擬收購寶中堂嶗山及寶中堂峨山的100%股權 增強公司在上海的市場份額
格隆匯7月5日丨固生堂(02273.HK)宣佈,於2023年7月5日,公司的附屬公司廣東固生堂中醫("中醫")養生健康科技股份有限公司("廣東固生堂")與上海寶中堂中醫門診部有限公司("寶中堂嶗山")的股東訂立股權轉讓協議及補充協議,據此,廣東固生堂有條件同意收購及寶中堂嶗山賣方有條件同意出售寶中堂嶗山的100%股權("寶中堂嶗山收購事項"),代價為人民幣6094.16萬元。
於寶中堂嶗山收購事項完成後,寶中堂嶗山將成為公司的間接全資附屬公司,且寶中堂嶗山的財務業績將併入集團的綜合財務報表。
同日宣佈,於2023年7月5日,公司的附屬公司廣東固生堂與上海寶中堂峨山中醫門診部有限公司("寶中堂峨山")的股東訂立股權轉讓協議,據此,廣東固生堂有條件同意收購及寶中堂峨山賣方有條件同意出售寶中堂峨山的100%股權,代價為人民幣783.02萬元。
於寶中堂峨山收購事項完成後,寶中堂峨山將成為公司的間接全資附屬公司,且寶中堂峨山的財務業績將併入集團的綜合財務報表。
據悉,寶中堂嶗山主要於中國(上海)自由貿易試驗區(嶗山路地區)從事一般中醫服務。於公吿日期,上海寶中堂中醫門診部已獲相關醫療保險部門批准為定點醫療機構,獲准治療由公共醫療保險計劃覆蓋的患者。寶中堂峨山主要於中國(上海)自由貿易試驗區(峨山路地區)從事一般中醫服務。於公吿日期,上海寶中堂峨山中醫門診部已獲相關醫療保險部門批准為定點醫療機構,獲准治療由公共醫療保險計劃覆蓋的患者。
公吿稱,寶中堂嶗山收購事項及寶中堂峨山收購事項符合集團通過收購擴大線下醫療機構網絡的擴張戰略,前提是公司認為寶中堂嶗山收購事項及寶中堂峨山收購事項將(其中包括)(i)增強公司在上海的市場份額及(ii)使寶中堂嶗山、寶中堂峨山與集團其他線下醫療機構及線上醫療平台之間形成協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.